Media ReleasesInnate Immunotherapeutics

View All Innate Immunotherapeutics News


Innate Immunotherapeutics, Gordon Capital Research Update

Capital Strategy to Deliver on Key Value Building Initiatives

Innate Immunotherapeutics has announced a two-stage capital raising to fund ongoing clinical efficacy trials and development of its proprietary MIS416 drug.

- Stage 1 involves a private placement of 10M shares at A$0.25/share to US investors

- Stage 2 is a 1 for 9 Non-Renounceable Rights Issue at an Issue Price of A$0.25/share to all eligible shareholders which will close on July 5 2016


To view Update please download PDF attached:
Download this document